News stories about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending somewhat negative on Friday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of -0.15 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 91 out of 100, meaning that recent news coverage is extremely likely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:
- AMAG Pharmaceuticals, Inc. (AMAG) noted a price change of 5.34 … – Stocks Gallery (stocksgallery.com)
- Clues to Identify Price Direction: AMAG Pharmaceuticals, Inc. (AMAG), Regeneron Pharmaceuticals, Inc. (REGN) – AllStockNews (allstocknews.com)
- Shares Seesawing on Volume: AMAG Pharmaceuticals Inc (AMAG) – Evergreen Caller (evergreencaller.com)
- Amag Pharmaceuticals (AMAG) Market Value Declined While Alphaone Investment Services Has Upped by $459000 … – BZ Weekly (bzweekly.com)
- Shares Seesawing on Volume: AMAG Pharmaceuticals Inc (AMAG … – Evergreen Caller (evergreencaller.com)
A number of analysts have recently issued reports on the stock. Barclays PLC reaffirmed a “hold” rating and set a $25.00 price objective on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. Cantor Fitzgerald lifted their price objective on shares of AMAG Pharmaceuticals from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, March 6th. TheStreet downgraded shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Jefferies Group LLC set a $40.00 price objective on shares of AMAG Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, April 20th. Finally, ValuEngine downgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $29.44.
Shares of AMAG Pharmaceuticals (NASDAQ AMAG) opened at 18.20 on Friday. AMAG Pharmaceuticals has a 1-year low of $16.00 and a 1-year high of $36.83. The company’s market capitalization is $637.82 million. The firm has a 50-day moving average of $18.26 and a 200 day moving average of $23.88.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The business had revenue of $139.47 million for the quarter, compared to the consensus estimate of $150.32 million. During the same quarter last year, the business earned ($0.22) EPS. AMAG Pharmaceuticals’s revenue for the quarter was up 27.6% compared to the same quarter last year. On average, analysts anticipate that AMAG Pharmaceuticals will post $5.09 EPS for the current year.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $24.45, for a total transaction of $46,234.95. Following the completion of the transaction, the senior vice president now owns 36,777 shares in the company, valued at $899,197.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.80% of the stock is owned by company insiders.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/amag-pharmaceuticals-amag-earning-somewhat-negative-news-coverage-report-finds/1933598.html
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.